Free tool
FAERS Monitor: Piqray
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212526 or its brand name (Piqray, Alpelisib). Reports on generic versions are filed under their own applications.
Reports
8,387
Serious
4,816
57% of reports
Hospitalization
1,655
Death reported
1,229
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hyperglycaemia1,498
- rash1,384
- diarrhoea1,320
- blood glucose increased1,120
- death900
- nausea847
- fatigue839
- decreased appetite541
- malignant neoplasm progression519
- weight decreased519
- vomiting484
- drug ineffective376
- asthenia345
- stomatitis331
- pruritus281
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 802 |
| 2020 | 1,738 |
| 2021 | 1,761 |
| 2022 | 1,704 |
| 2023 | 1,386 |
| 2024 | 504 |
| 2025 | 266 |
| 2026 | 214 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,772 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperglycaemiaSignal | 1,498 | 107.5 | 102.5 | 151,684 |
| blood glucose increasedSignal | 1,120 | 15.0 | 14.2 | 14,655 |
| stomatitisSignal | 331 | 13.8 | 12.4 | 3,892 |
| malignant neoplasm progressionSignal | 519 | 12.8 | 11.7 | 5,617 |
| rashSignal | 1,384 | 8.0 | 7.6 | 8,600 |
| decreased appetiteSignal | 541 | 5.9 | 5.4 | 2,191 |
| diarrhoeaSignal | 1,320 | 5.1 | 4.9 | 4,523 |
| weight decreasedSignal | 519 | 4.7 | 4.3 | 1,510 |
| fatigueSignal | 839 | 2.7 | 2.5 | 933 |
| nauseaSignal | 847 | 2.7 | 2.5 | 928 |
| deathSignal | 900 | 2.6 | 2.5 | 939 |
| vomitingSignal | 484 | 2.6 | 2.4 | 478 |
| astheniaSignal | 345 | 2.3 | 2.1 | 257 |
| pruritus | 281 | 1.8 | 1.6 | 108 |
| drug ineffective | 376 | 0.7 | 0.6 | 45 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.